Barber David S, LoPachin Richard M
Center for Human and Environmental Toxicology, University of Florida, Gainesville, FL 32611, USA.
Toxicol Appl Pharmacol. 2004 Dec 1;201(2):120-36. doi: 10.1016/j.taap.2004.05.008.
Evidence suggests that the neurological defects (gait abnormalities, foot splay, and skeletal muscle weakness) associated with acrylamide (ACR) intoxication are mediated by impaired neurotransmission at central and peripheral synapses. ACR can form adducts with nucleophilic residues on proteins and thereby alter corresponding structure and function. To evaluate protein adduction in nerve terminals as a possible mechanism of action, recombinant N-ethylmaleimide sensitive factor (NSF) was exposed in vitro to ACR (10 micromol) and mass spectrometry (MS) was used to identify adduct sites. MS analyses demonstrated that ACR formed adducts with sulfhydryl groups on cysteine residues (carbamoylethylcysteine, or CEC) of NSF. Ex vivo incubation of whole brain synaptosomes with ACR (0.001-1.0 M) produced concentration-dependent increases in CEC that were inversely correlated to reductions in neurotransmitter release that occurred over the same neurotoxicant concentration range. In synaptosomes isolated from rats intoxicated at a higher (50 mg/kg per day x 3, 5, 8, or 11 days) or a lower (21 mg/kg per day x 14, 21, or 28 day) ACR dose rate, CEC levels increased progressively up to a moderate level of neurotoxicity. To identify protein adducts, synaptosomal proteins labeled by ex vivo 14C-ACR exposure were separated by gel electrophoresis and probed by immunoblot analysis. Results showed that NSF and the SNARE protein, SNAP-25, were tentative ACR targets. Subsequent experiments indicated that ACR exposure increased synaptosomal levels of the 7S SNARE core complex, which is consistent with inhibition of NSF, SNAP-25 function, or both. These data suggest that adduction of cysteine residues on NSF and certain SNARE proteins might be causally involved in the nerve terminal dysfunction induced by ACR.
有证据表明,与丙烯酰胺(ACR)中毒相关的神经学缺陷(步态异常、足展和骨骼肌无力)是由中枢和外周突触处神经传递受损介导的。ACR可与蛋白质上的亲核残基形成加合物,从而改变相应的结构和功能。为了评估神经末梢中的蛋白质加合作为一种可能的作用机制,将重组N - 乙基马来酰亚胺敏感因子(NSF)在体外暴露于ACR(10微摩尔),并使用质谱(MS)鉴定加合位点。MS分析表明,ACR与NSF半胱氨酸残基上的巯基形成加合物(氨甲酰乙基半胱氨酸,或CEC)。用ACR(0.001 - 1.0 M)对全脑突触体进行离体孵育,导致CEC呈浓度依赖性增加,且与在相同神经毒物浓度范围内发生的神经递质释放减少呈负相关。在从以较高(50毫克/千克/天×3、5、8或11天)或较低(21毫克/千克/天×14、21或28天)ACR剂量率中毒的大鼠中分离出的突触体中,CEC水平逐渐升高,直至达到中度神经毒性水平。为了鉴定蛋白质加合物,通过凝胶电泳分离经离体14C - ACR暴露标记的突触体蛋白,并通过免疫印迹分析进行检测。结果显示,NSF和SNARE蛋白SNAP - 25是ACR的潜在靶点。随后的实验表明,ACR暴露增加了7S SNARE核心复合物的突触体水平,这与NSF、SNAP - 25功能的抑制或两者均被抑制一致。这些数据表明,NSF和某些SNARE蛋白上半胱氨酸残基的加合可能与ACR诱导的神经末梢功能障碍有因果关系。